SCHEMBL6586902

SCHEMBL6586902

NS(=O)(=O)c1ccsc1C(=O)NCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.62
CA2 P00918 12/20 0.55
EDNRB P24530 1/20 0.54
EDNRA P25101 1/20 0.54
CA1 P00915 11/20 0.54
CA12 O43570 8/20 0.54
CA9 Q16790 8/20 0.54
CA5A P35218 5/20 0.54
CA7 P43166 5/20 0.54
CA5B Q9Y2D0 5/20 0.54
CA3 P07451 4/20 0.54
CA6 P23280 4/20 0.54
CA13 Q8N1Q1 4/20 0.54
CA14 Q9ULX7 4/20 0.54
CA4 P22748 4/20 0.54
LMNA P02545 1/20 0.48
PTGS2 P35354 1/20 0.46
SCN3A Q9NY46 1/20 0.46
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3679663 0.81 KMT2A (0.55) KMT2ALMNAPTGS2ALDH1A1HPGD
SCHEMBL27455220 0.78 MAPK8 (0.46) KMT2ACA2EDNRBEDNRACA1
SCHEMBL27456266 0.78 EDNRA (0.54) KMT2ACA2EDNRBEDNRACA1
SCHEMBL3049318 0.77 KMT2A (0.66) KMT2AEDNRBEDNRAPTGS2ALDH1A1
SCHEMBL5247128 0.74 CA2 (0.54) KMT2ACA2CA1CA12CA9
SCHEMBL5208861 0.73 LMNA (0.62) KMT2AEDNRALMNA
SCHEMBL8419350 0.72 CA2 (0.61) KMT2ACA2CA1CA12CA9
SCHEMBL28756346 0.71 GRM5 (0.51) KMT2ALMNAPTGS2ALDH1A1HPGD
SCHEMBL7613280 0.71 EDNRA (0.57) CA2EDNRBEDNRACA1CA12
SCHEMBL678390 0.71 CA2 (1.00) CA2CA1CA12CA9CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100558724-C Adjust active sulphonamide of endothelium peptide and derivative thereof ANSEHIV PHARMACEUTICAL CORP (US) 2009-11-11 CN disclosed
CN-1215069-C Sulfonamides and derivatives thereof that modulate the activity of endothelin ENCYSIVE PHARMACEUTICALS INC (US) 2005-08-17 CN disclosed
EP-1244657-B1 SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN ENCYSIVE PHARMACEUTICALS INC (US) 2004-12-29 EP disclosed
CN-1530366-A Sulphonic acid amide for regulating bast peptide activity and derivative thereof ��ɪϣ����ҩ��˾ 2004-09-22 CN disclosed
EP-0946552-B1 SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN ENCYSIVE PHARMACEUTICALS INC (US) 2004-07-07 EP disclosed
US-6686382-B2 N-(ISOXAZOLYL)THIENYLSULFONAMIDES, N-(ISOXAZOLYL)FURYLSULFONAMIDES, N-(ISOXAZOLYL)PYRROLYLSULFONAMIDES AND N-(ISOXAZOLYL)PHENYLSULFONAMIDES; INHIBIT ENDOTHELIN ENCYSIVE PHARMACEUTICALS INC. 2004-02-03 US disclosed
US-20030208084-A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin ENCYSIVE PHARMACEUTICALS INC. 2003-11-06 US disclosed
US-6632829-B2 Thienyl, furyl and pyrrolyl-sulfonamides, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure and other diseases TEXAS BIOTECHNOLOGY CORP. 2003-10-14 US disclosed
EP-1342721-A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin ENCYSIVE PHARMACEUTICALS INC. (US) 2003-09-10 EP disclosed
EP-1244657-A2 SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-10-02 EP disclosed
US-20020091272-A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin ENCYSIVE PHARMACEUTICALS INC. 2002-07-11 US disclosed
US-20010056183-A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORPORATION 2001-12-27 US disclosed
WO-2001049685-A2 SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 2001-07-12 WO disclosed
CN-1231664-A Sulfonamides and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORP (US) 1999-10-13 CN disclosed
EP-0946552-A1 SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1999-10-06 EP disclosed
WO-1998013366-A1 SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030208084-A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin EDNRA, EDNRB, ECE1 KMT2A 3411/4885CA2 922/4885EDNRB 2/4885
US-20010056183-A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin EDNRA, EDNRB, ECE1 KMT2A 3597/4885CA2 1646/4885EDNRB 2/4885
US-20020091272-A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin EDNRA, EDNRB, ECE1 KMT2A 3411/4885CA2 922/4885EDNRB 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.